Search This Blog

Friday, November 9, 2018

Perrigo share valuation should rebound, says Canaccord


Canaccord analyst Dewey Steadman said Perrigo posted a decent quarter for its core consumer businesses but saw softness in its prescription generics unit. The company has been trying to sell the unit, but he expects guidance to be soft as the business weighs on near-term results. The analyst said he expects the share price to rebound as the company emerges from its strategic challenges. Steadman maintained his Buy rating and $90 price target on Perrigo shares.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.